High-Dose Methotrexate for Osteosarcoma: Toxicity and Clinical Results
Authors:
- Henning BreithauptHBHenning Breithaupt
- Eberhard KüenzlenEKEberhard Küenzlen
- 1 January 1983
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 40 (2) , 85-89
Abstract
9 patients with osteosarcoma were treated with a total of 122 infusions of high-dose methotrexate (MTX; 140–350 mg/kg) followed by leucovorin rescue. Plasma kinetics of MTX and 7-hydroxymethotrexate (7-OH-MTX) has been routinely monitored. Due to inadequate hydration and alkalinization, 1 of the 122 high-dose MTX infusions was followed by delayed disappearance of MTX and 7-OH-MTX from plasma with subsequent development of severe mucositis. Serious hepatotoxicity repeatedly developed in another patient with inconspicuous MTX kinetics. The benefit of monotherapy with high-dose MTX for adjuvant treatment of osteosarcoma remains questionable, since 6 of 8 patients with primary osteosarcoma developed pulmonary metastases within 4–12 months (median 5 months), 2 have been disease-free and alive for 25 and 53 months.Keywords
This publication has 6 references indexed in Scilit:
- Rapid high-pressure liquid chromatographic determination of methotrexate and its metabolites 7-hydroxymethotrexate and 2,4-diamino-N10-methylpteroic acid in biological fluidsAnalytical Biochemistry, 1982
- TREATMENT OF OSTEOGENIC-SARCOMA .1. EFFECT OF ADJUVANT HIGH-DOSE METHOTREXATE AFTER AMPUTATION1979
- Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate ToxicityNew England Journal of Medicine, 1977
- HIGH-DOSE METHOTREXATE WITH CITROVORUM FACTOR RESCUE - PREDICTIVE VALUE OF SERUM METHOTREXATE CONCENTRATIONS AND CORRECTIVE MEASURES TO AVERT TOXICITY1977
- Osteogenic SarcomaJournal of Bone and Joint Surgery, 1967
- The Prognosis of Osteosarcoma: An Analytical StudyBritish Journal of Radiology, 1966